Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050232 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
A Phase 3 study, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
NCT00050232 is a Phase 3 study that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 96 participants.
The verdict
NCT00050232, a Phase 3 study, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
Study Summary
Pseudobulbar Affect is a condition characterized by frequent episodes of laughing and crying out of proportion. Other terms used to describe this condition include emotional lability, emotionalism, emotion incontinence, emotional discontrol, excessive emotionalism and pathological laughing and crying. AVP-923 is a new experimental drug that may assist in the reduction of uncontrolled episodes. This study will test the safety and efficacy of AVP-923 in the treatment of MS patients suffering from pseudobulbar affect.
Interventions
- DRUG AVP-923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2002-12 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050232
The ClinicalTrials.gov registry entry for NCT00050232 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVP-923 is the first listed.
NCT00050232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050232 about?
NCT00050232 is a clinical study titled "Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients". Pseudobulbar Affect is a condition characterized by frequent episodes of laughing and crying out of proportion. Other terms used to describe this condition include emotional lability, emotionalism, emotion incontinence, emotional discontrol, excessive emotionalism and pathological laughing and cryin...
What is the current status of trial NCT00050232?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2002-12. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00050232?
The interventions under investigation include: AVP-923 (DRUG).
Who is sponsoring clinical trial NCT00050232?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.